N. Raiimbek Uulu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
N. Raiimbek Uulu has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Begimai Akbalaeva
Ошский государственный университет, Ош
4 shared publications - Larisa V. Shulzhenko
Kuban State Medical University
4 shared publications - O. V. Gurovich
Burdenko Voronezh State Medical University, Voronezh
4 shared publications - Romanbek Kalmatov
Osh State University
4 shared publications - Talantbek A. Batyraliev
Salymbekov University, Bishkek
4 shared publications - V. V. Vinogradskaia
City of Health Clinic, Voronezh
4 shared publications
Latest Publications
- 7 July 2025
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 65 (6) , 34-43
The Joint Role of Serum Markers of Congestion or Myocardial Necrosis And Speckle Tracking Echocardiography in The Detection of Early Subtle Chemotherapy-Induced Cardiotoxicity in Women With Breast Cancer
Aim To monitor the dynamics of biomarkers during chemotherapy, targeted chemotherapy and targeted monotherapy in patients with HER2-positive breast cancer (BC); to analyze the emergence timing of these changes; to compare early biochemical and echocardiographic criteria; and to determine the best time for assessing latent subclinical cardiac dysfunction. Material and methods Patients with BC (229 women aged 57±11 years) treated sequentially with anthracyclines, a combination of docetaxel and trastuzumab, and trastuzumab monotherapy were examined during three blocks of BC therapy until the development of clinical cardiotoxicity. Time-related changes in high-sensitivity cardiac troponin I, N-terminal pro-brain natriuretic peptide (NT-proBNP), left ventricular (LV) global longitudinal strain (GLS) and LV ejection fraction (EF) (up to 12 speckle-tracking echocardiograms/up to 12 laboratory tests) were analyzed. Clinical cardiotoxicity was defined as a symptomatic decrease in LV EF ≥10% from the baseline value of 54% or more. Results Clinically significant cardiotoxicity developed in 6.3-10.9% of cases depending on the treatment option for BC. Early manifestations of cardiotoxicity were detected already at 3 weeks after the start of the first course of chemotherapy. For the BC treatment with anthracyclines and targeted chemotherapy with docetaxel and trastuzumab, the markers of clinical cardiotoxicity were high-sensitivity cardiac troponin I, NT-proBNP and GLS LV. For the trastuzumab monotherapy, only GLS LV had a prognostic value. No statistically significant changes in the concentrations of high-sensitivity troponin I and NT-proBNP were found. Conclusion For timely detection of clinical cardiotoxicity, laboratory tests (high-sensitivity troponin I, NT-proBNP) and echocardiography (GLS LV) are recommended to be performed every 3 weeks before the next course of BC therapy. While doing so, their sensitivity will depend on the treatment option for BC.
- 7 July 2025
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 65 (6) , 34-43
The Joint Role of Serum Markers of Congestion or Myocardial Necrosis And Speckle Tracking Echocardiography in The Detection of Early Subtle Chemotherapy-Induced Cardiotoxicity in Women With Breast Cancer
Aim To monitor the dynamics of biomarkers during chemotherapy, targeted chemotherapy and targeted monotherapy in patients with HER2-positive breast cancer (BC); to analyze the emergence timing of these changes; to compare early biochemical and echocardiographic criteria; and to determine the best time for assessing latent subclinical cardiac dysfunction. Material and methods Patients with BC (229 women aged 57±11 years) treated sequentially with anthracyclines, a combination of docetaxel and trastuzumab, and trastuzumab monotherapy were examined during three blocks of BC therapy until the development of clinical cardiotoxicity. Time-related changes in high-sensitivity cardiac troponin I, N-terminal pro-brain natriuretic peptide (NT-proBNP), left ventricular (LV) global longitudinal strain (GLS) and LV ejection fraction (EF) (up to 12 speckle-tracking echocardiograms/up to 12 laboratory tests) were analyzed. Clinical cardiotoxicity was defined as a symptomatic decrease in LV EF ≥10% from the baseline value of 54% or more. Results Clinically significant cardiotoxicity developed in 6.3-10.9% of cases depending on the treatment option for BC. Early manifestations of cardiotoxicity were detected already at 3 weeks after the start of the first course of chemotherapy. For the BC treatment with anthracyclines and targeted chemotherapy with docetaxel and trastuzumab, the markers of clinical cardiotoxicity were high-sensitivity cardiac troponin I, NT-proBNP and GLS LV. For the trastuzumab monotherapy, only GLS LV had a prognostic value. No statistically significant changes in the concentrations of high-sensitivity troponin I and NT-proBNP were found. Conclusion For timely detection of clinical cardiotoxicity, laboratory tests (high-sensitivity troponin I, NT-proBNP) and echocardiography (GLS LV) are recommended to be performed every 3 weeks before the next course of BC therapy. While doing so, their sensitivity will depend on the treatment option for BC.
- 15 June 2025
- Published by Publishing Center Science and Practice in Bulletin of Science and Practice
- Vol. 11 (6) , 186-195
Peculiarities of Manifestation and Modification of Cardiovascular Risk Factors in Urban and Rural Residents
Timely identification of risk factors is an important step towards reducing morbidity, since it will allow for the timely development of a set of treatment and preventive measures with minimal resource and economic costs, with minimal reduction in the quality of life of both the patient and his immediate environment. The main target guidelines are early detection of people with high risks of cardiovascular pathology, reduction of the level of impact of these factors, and maintenance of the highest possible percentage of people with a minimum level of risk of developing CVD. It is necessary to single out in a separate category people who have a history of diseases that can become a trigger for cardiovascular pathology. To study the current state of the problem of cardiovascular diseases (CVD) in rural and urban residents. The presented article is of a review nature, which determines the use of theoretical research methods. In writing the work, we used the following methodological approaches: meta-analysis of literary sources, critical and conceptual analysis. High blood pressure (BP), high glucose and cholesterol levels in the blood of patients are grounds for increased monitoring. It is important to identify the risk of developing atherosclerosis long before the first signs appear. Conclusions: risk factors should be assessed continuously and should be carried out whenever a patient seeks medical care. It is also important to involve local therapists in systematic monitoring of the cardiovascular system based on specially developed criteria for express diagnostics.
- 15 June 2025
- Published by Publishing Center Science and Practice in Bulletin of Science and Practice
- Vol. 11 (6) , 186-195
Peculiarities of Manifestation and Modification of Cardiovascular Risk Factors in Urban and Rural Residents
Timely identification of risk factors is an important step towards reducing morbidity, since it will allow for the timely development of a set of treatment and preventive measures with minimal resource and economic costs, with minimal reduction in the quality of life of both the patient and his immediate environment. The main target guidelines are early detection of people with high risks of cardiovascular pathology, reduction of the level of impact of these factors, and maintenance of the highest possible percentage of people with a minimum level of risk of developing CVD. It is necessary to single out in a separate category people who have a history of diseases that can become a trigger for cardiovascular pathology. To study the current state of the problem of cardiovascular diseases (CVD) in rural and urban residents. The presented article is of a review nature, which determines the use of theoretical research methods. In writing the work, we used the following methodological approaches: meta-analysis of literary sources, critical and conceptual analysis. High blood pressure (BP), high glucose and cholesterol levels in the blood of patients are grounds for increased monitoring. It is important to identify the risk of developing atherosclerosis long before the first signs appear. Conclusions: risk factors should be assessed continuously and should be carried out whenever a patient seeks medical care. It is also important to involve local therapists in systematic monitoring of the cardiovascular system based on specially developed criteria for express diagnostics.
- Open Access
- 10 June 2024
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 23 (6) , 4038
Echo-loop of subclinical cardiovascular toxicity in women associated with HER2-positive breast cancer therapy
Aim. To assess the incidence and timing of subclinical cardiac dysfunction associated with therapy for HER2-positive locally advanced or metastatic breast cancer, and to analyze the difference in time from significant reduction in left ventricular (LV) global longitudinal strain (GLS) to significant reduction in LV ejection fraction (LVEF) (cardiotoxicity "echo-loop").Material and methods. A total of 187 women 58±11 years without baseline cardiac dysfunction with verified HER2-positive locally advanced or metastatic breast cancer who received sequential adjuvant therapy with doxorubicin+cyclophosphamide, docetaxel+trastuzumab and trastuzumab monotherapy were followed up in 4 centers in four countries within 12 months with regular (every 3 weeks) speckle-tracking echocardiographic monitoring.Results. Subclinical cardiac dysfunction associated with breast cancer therapy (CTRCD) appears in each block of therapy after the first course. Its frequency increases significantly after each subsequent course compared to the previous one. By the end of the 4th course in each block of therapy, subclinical CTRCD is noted from 24,6% (almost every 4th patient in the chemotherapy block) to 32,6-33,7% (almost every 3rd patient in the chemotherapy and targeted therapy blocks). In 24 out of 25 cases of severe subclinical CTRCD (96%) with a fall in LVEF 15% was preceded. The time difference from a decrease in LV GLS to a decrease in LVEF Conclusion. Until recently, the period of identified moderate subclinical cardiac dysfunction was not used to prescribe therapy for the prevention and treatment of cardiotoxicity. Enhanced speckle-tracking echocardiographic monitoring may reduce the incidence of severe subclinical and overt clinical cardiac dysfunction. Guidelines for cardiotoxicity monitoring should be reviewed to reduce the incidence of severe cardiac complications of cancer therapy.
- 10 June 2024
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 23 (6) , 4038
Open AccessEcho-loop of subclinical cardiovascular toxicity in women associated with HER2-positive breast cancer therapy
Aim. To assess the incidence and timing of subclinical cardiac dysfunction associated with therapy for HER2-positive locally advanced or metastatic breast cancer, and to analyze the difference in time from significant reduction in left ventricular (LV) global longitudinal strain (GLS) to significant reduction in LV ejection fraction (LVEF) (cardiotoxicity "echo-loop").Material and methods. A total of 187 women 58±11 years without baseline cardiac dysfunction with verified HER2-positive locally advanced or metastatic breast cancer who received sequential adjuvant therapy with doxorubicin+cyclophosphamide, docetaxel+trastuzumab and trastuzumab monotherapy were followed up in 4 centers in four countries within 12 months with regular (every 3 weeks) speckle-tracking echocardiographic monitoring.Results. Subclinical cardiac dysfunction associated with breast cancer therapy (CTRCD) appears in each block of therapy after the first course. Its frequency increases significantly after each subsequent course compared to the previous one. By the end of the 4th course in each block of therapy, subclinical CTRCD is noted from 24,6% (almost every 4th patient in the chemotherapy block) to 32,6-33,7% (almost every 3rd patient in the chemotherapy and targeted therapy blocks). In 24 out of 25 cases of severe subclinical CTRCD (96%) with a fall in LVEF 15% was preceded. The time difference from a decrease in LV GLS to a decrease in LVEF Conclusion. Until recently, the period of identified moderate subclinical cardiac dysfunction was not used to prescribe therapy for the prevention and treatment of cardiotoxicity. Enhanced speckle-tracking echocardiographic monitoring may reduce the incidence of severe subclinical and overt clinical cardiac dysfunction. Guidelines for cardiotoxicity monitoring should be reviewed to reduce the incidence of severe cardiac complications of cancer therapy.
- Open Access
- 28 April 2024
- Published by Scientific Research Institute - Ochapovsky Regional Clinical Hospital No 1 in Innovative Medicine of Kuban
- No. 2,p. 8-15
Speckle-Tracking Echocardiography in Assessment of Breast Cancer Therapy-Related Subclinical Cardiac Dysfunction
Background: Cancer therapy-related cardiac dysfunction (CTRCD) is a new term that encompasses a wide range of potential manifestations and is etiologically associated with a wide variety of cancer treatments. Detection of early subclinical cardiac dysfunction is of great clinical importance.Objective: To assess subclinical CTRCD in women with HER2-positive locally advanced or metastatic breast cancer undergoing a course of anthracyclines (doxorubicin), docetaxel, and trastuzumab. We prospectively enrolled women aged 18-75 years with an established diagnosis of HER2-positive locally advanced or metastatic breast cancer across 3 centers.Material and methods: We monitored 122 women with HER2-positive locally advanced or metastatic breast cancer undergoing a course of anthracyclines (doxorubicin), docetaxel, and trastuzumab using speckle-tracking echocardiography. Based on the treatment protocol, we formed 3 comparison blocks: block 1 (chemotherapy: doxorubicin+cyclophosphamide); block 2 (chemotherapy+targeted therapy: docetaxel+trastuzumab), and block 3 (targeted therapy: trastuzumab).Results: The rate of subclinical CTRCD detection was high and exceeded 20%-30% in all comparison blocks after the 3rd course of chemotherapy, chemotherapy+targeted therapy, and targeted therapy. The rate of subclinical CTRCD increased significantly from the 1st to the 2nd, from the 2nd to the 3rd, from the 3rd to the 4th therapy courses in each block. Comparisons between the blocks were significant only after the 4th course of chemotherapy and the 4th course of targeted therapy (Yates-corrected chi-square, P=.0394); all the other comparisons between the blocks were not significant in terms of subclinical CTRCD rate.Discussion: Given the growing number of patients with breast cancer, such frequent monitoring of the cardiac function is likely to improve the quality of cancer treatment and might have a positive impact on the overall survival of patients with breast cancer. Conclusions: Criteria for frequency of echocardiographic monitoring of cardiac dysfunction in patients with malignant tumors, especially with HER2-positive breast cancer, should be revised.
- 28 April 2024
- Published by Scientific Research Institute - Ochapovsky Regional Clinical Hospital No 1 in Innovative Medicine of Kuban
- No. 2,p. 8-15
Open AccessSpeckle-Tracking Echocardiography in Assessment of Breast Cancer Therapy-Related Subclinical Cardiac Dysfunction
Background: Cancer therapy-related cardiac dysfunction (CTRCD) is a new term that encompasses a wide range of potential manifestations and is etiologically associated with a wide variety of cancer treatments. Detection of early subclinical cardiac dysfunction is of great clinical importance.Objective: To assess subclinical CTRCD in women with HER2-positive locally advanced or metastatic breast cancer undergoing a course of anthracyclines (doxorubicin), docetaxel, and trastuzumab. We prospectively enrolled women aged 18-75 years with an established diagnosis of HER2-positive locally advanced or metastatic breast cancer across 3 centers.Material and methods: We monitored 122 women with HER2-positive locally advanced or metastatic breast cancer undergoing a course of anthracyclines (doxorubicin), docetaxel, and trastuzumab using speckle-tracking echocardiography. Based on the treatment protocol, we formed 3 comparison blocks: block 1 (chemotherapy: doxorubicin+cyclophosphamide); block 2 (chemotherapy+targeted therapy: docetaxel+trastuzumab), and block 3 (targeted therapy: trastuzumab).Results: The rate of subclinical CTRCD detection was high and exceeded 20%-30% in all comparison blocks after the 3rd course of chemotherapy, chemotherapy+targeted therapy, and targeted therapy. The rate of subclinical CTRCD increased significantly from the 1st to the 2nd, from the 2nd to the 3rd, from the 3rd to the 4th therapy courses in each block. Comparisons between the blocks were significant only after the 4th course of chemotherapy and the 4th course of targeted therapy (Yates-corrected chi-square, P=.0394); all the other comparisons between the blocks were not significant in terms of subclinical CTRCD rate.Discussion: Given the growing number of patients with breast cancer, such frequent monitoring of the cardiac function is likely to improve the quality of cancer treatment and might have a positive impact on the overall survival of patients with breast cancer. Conclusions: Criteria for frequency of echocardiographic monitoring of cardiac dysfunction in patients with malignant tumors, especially with HER2-positive breast cancer, should be revised.
- Open Access
- 26 December 2023
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 63 (12) , 31-38
The Clinical Evolution of Diffuse Myocardial Fibrosis in Patients With Arterial Hypertension and Heart Failure With Mildly Reduced Ejection Fraction Treated by Olmesartan or Sacubitril / Valsartan
Aim A 12-month evaluation of the potentialities of the angiotensin II receptor inhibitor olmesartan (Olme) and the angiotensin receptor and neprilysin inhibitor (ARNI) sacubitril/valsartan in patients with arterial hypertension (AH) and dyslipidemia in the dynamics of the following indicators of chronic heart failure (CHF): N-terminal pro-brain natriuretic peptide (NT-proBNP), left ventricular ejection fraction (LVEF), LV global longitudinal strain (LV GLS) in diffuse myocardial fibrosis (MF) previously diagnosed by magnetic resonance imaging (MRI). Material and methods Olmesartan medoxomil (n=56) and sacubitril/valsartan (n=63) were used for 12 months in patients with hypertension, dyslipidemia and NYHA functional class II-III CHF with mid-range LVEF (CHFmrEF). MF was diagnosed by the following MRI criteria: late gadolinium enhancement and an increased proportion of extracellular matrix (33% or more). The frequency of persisting late gadolinium enhancement and the increased proportion of extracellular matrix (33% or more) was evaluated at 12 months; changes in systolic blood pressure (SBP), diastolic blood pressure (DBP), NT-proBNP, and LV GLS were evaluated after 3, 6, and 12 months of follow-up. Results Baseline parameters did not differ between groups. The late gadolinium enhancement and increased proportion of extracellular matrix were present at baseline in all patients of both groups (100%; p=1.0). Already at 3 months, statistically significant decreases in SBP and DBP were observed in both groups. In addition, the LV GLS monitoring showed LV GLS significantly increased in both groups after 3 months and continued changing after 6 and 12 months. The NT-proBNP concentration significantly decreased in both groups already after 3 months and continued to decrease after 6 and 12 months. At 6 and 12 months, sacubitril/valsartan was superior to olmesartan in reducing SBP and NT-proBNP and in restoring LV GLS. At 12 months, the incidence of persisting, abnormal late gadolinium enhancement and increased proportion of extracellular matrix was significantly less in the ARNI group. Conclusion Olmesartan was demonstrated effective in the multi-modality therapy of CHFmrEF and MF in patients with AH and dyslipidemia. ARNI was superior to olmesartan in this regard, but further research of this issue is required.
- 26 December 2023
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 63 (12) , 31-38
Open AccessThe Clinical Evolution of Diffuse Myocardial Fibrosis in Patients With Arterial Hypertension and Heart Failure With Mildly Reduced Ejection Fraction Treated by Olmesartan or Sacubitril / Valsartan
Aim A 12-month evaluation of the potentialities of the angiotensin II receptor inhibitor olmesartan (Olme) and the angiotensin receptor and neprilysin inhibitor (ARNI) sacubitril/valsartan in patients with arterial hypertension (AH) and dyslipidemia in the dynamics of the following indicators of chronic heart failure (CHF): N-terminal pro-brain natriuretic peptide (NT-proBNP), left ventricular ejection fraction (LVEF), LV global longitudinal strain (LV GLS) in diffuse myocardial fibrosis (MF) previously diagnosed by magnetic resonance imaging (MRI). Material and methods Olmesartan medoxomil (n=56) and sacubitril/valsartan (n=63) were used for 12 months in patients with hypertension, dyslipidemia and NYHA functional class II-III CHF with mid-range LVEF (CHFmrEF). MF was diagnosed by the following MRI criteria: late gadolinium enhancement and an increased proportion of extracellular matrix (33% or more). The frequency of persisting late gadolinium enhancement and the increased proportion of extracellular matrix (33% or more) was evaluated at 12 months; changes in systolic blood pressure (SBP), diastolic blood pressure (DBP), NT-proBNP, and LV GLS were evaluated after 3, 6, and 12 months of follow-up. Results Baseline parameters did not differ between groups. The late gadolinium enhancement and increased proportion of extracellular matrix were present at baseline in all patients of both groups (100%; p=1.0). Already at 3 months, statistically significant decreases in SBP and DBP were observed in both groups. In addition, the LV GLS monitoring showed LV GLS significantly increased in both groups after 3 months and continued changing after 6 and 12 months. The NT-proBNP concentration significantly decreased in both groups already after 3 months and continued to decrease after 6 and 12 months. At 6 and 12 months, sacubitril/valsartan was superior to olmesartan in reducing SBP and NT-proBNP and in restoring LV GLS. At 12 months, the incidence of persisting, abnormal late gadolinium enhancement and increased proportion of extracellular matrix was significantly less in the ARNI group. Conclusion Olmesartan was demonstrated effective in the multi-modality therapy of CHFmrEF and MF in patients with AH and dyslipidemia. ARNI was superior to olmesartan in this regard, but further research of this issue is required.